Daclatasvir coming to a pharmacy near you soon?

August 20, 2015:  Today we received news that another upcoming drug, daclatasvir (Daklinza™) from Bristol-Myers Squibb, has received a Notice of Compliance from Health Canada. It is already being considered for coverage by British Columbia's Pharmacare, though it has not yet been approved. This drug is unique in its potential to mix and match with other drugs in order to treat a variety of genotypes, including hard-to-treat genotype 3 (combined with Gilead

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

Bristol-Myers Squibb’s “Stand-Alone” marketing of daclatasvir worldwide refreshing change

Amadou Diarra, Bristol-Myers Squibb Vice President, Global Policy & Government Affairs, source BMS website We recently praised the Bristol-Myers Squibb (BMS) marketing of daclatasvir as a 'stand-alone' hepatitis C drug which could be easily marketed and combined with other drugs instead of being packaged only with other drugs from the same company in a proprietary "package" (http://hepcbc.ca/2014/10/praise-stand-alone-hcv-drugs/). When our goal is th

In Praise of Stand-Alone HCV Drugs

BMS recently withdrew its US FDA application for the hepatitis C drug, asunaprevir. It is probably a very wise decision on BMS' part, because asunaprevir is close in formulation and results to several other generation 2 NS3 protease inhibitors*. Instead, BMS seems to be focusing on its more unique product, the NS5A replication complex inhibitor, daclatasvir, of which they say in their Oct. 7 press release, is "currently being investigated globally in multi

Fighting to make HCV treatment affordable for 170 million people

Bangkok, Thailand, Feb. 28, 2014 (press release): "Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection t